Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Aileron Therapeutics completes patient enrollment in Cohort 2 of phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis: Austin, Texas Wednesday, September 25, 2024, 15:00 Hrs ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

Ade Omisakin has managed to demolish the U83KG IPF Raw Total World Record at the 2024 IPF Western European Powerlifting ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

Brittany Schlater dominated the 2024 CPU Canadian National Championships and unofficially broke the Raw Deadlift IPF World ...

R&D image Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, ...

Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Boehringer Ingelheim said that it will submit a new drug application for nerandomilast based on the positive results.